Takeda set to target EU market with Adcetris following CHMP nod

 
• By Alexandra Shimmings

Takeda looks set to obtain EU marketing approval for Adcetris (brentuximab vedotin) for the treatment of Hodgkin's lymphoma following a positive opinion from the CHMP.

More from Alimentary/Metabolic

More from Therapy Areas